Cargando…
Anti–SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients
OBJECTIVE: To investigate the pathophysiologic mechanism of encephalopathy and prolonged comatose or stuporous state in severally ill patients with coronavirus disease 2019 (COVID-19). METHODS: Eight COVID-19 patients with signs of encephalopathy were tested for antibodies to severe acute respirator...
Autores principales: | Alexopoulos, Harry, Magira, Eleni, Bitzogli, Kleopatra, Kafasi, Nikolitsa, Vlachoyiannopoulos, Panayiotis, Tzioufas, Athanasios, Kotanidou, Anastasia, Dalakas, Marinos C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577546/ https://www.ncbi.nlm.nih.gov/pubmed/32978291 http://dx.doi.org/10.1212/NXI.0000000000000893 |
Ejemplares similares
-
Anti-SARS-CoV-2 antibody detection in healthcare workers of two tertiary hospitals in Athens, Greece
por: Vlachoyiannopoulos, Panayiotis, et al.
Publicado: (2020) -
Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications
por: Dalakas, Marinos C., et al.
Publicado: (2021) -
Late and booster anti‐SARS‐CoV‐2 humoral responses in nonresponder vaccinated patients with rheumatic diseases receiving mycophenolate or rituximab: comment on the article by XXX et al
por: Bakasis, Athanasios‐Dimitrios, et al.
Publicado: (2022) -
Incidence and Prevalence of Major Central Nervous System Involvement in Systemic Lupus Erythematosus: A 3-Year Prospective Study of 370 Patients
por: Kampylafka, Eleni I., et al.
Publicado: (2013) -
Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis
por: Kosmidis, Michalis L., et al.
Publicado: (2019)